StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Equities research analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays cut their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Price Performance

CLLS stock opened at $1.56 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The firm has a 50 day moving average price of $1.87 and a 200-day moving average price of $2.04. Cellectis has a 52-week low of $1.53 and a 52-week high of $3.55. The firm has a market capitalization of $86.71 million, a price-to-earnings ratio of -1.20 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The company had revenue of $18.05 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same quarter in the previous year, the firm posted ($0.31) EPS. Equities research analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Trading of Cellectis

A number of institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. boosted its position in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Cellectis during the 2nd quarter valued at about $29,000. Long Focus Capital Management LLC boosted its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares during the last quarter. Finally, First Affirmative Financial Network bought a new stake in shares of Cellectis in the third quarter worth approximately $45,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.